Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia

Publication Date: May 17, 2024
Last Updated: May 31, 2024

Summary of Recommendations

General Implementation Considerations

  • In patients with BE, counsel tobacco cessation and weight loss if overweight.
  • Refer patients with dysplastic BE to high-volume endoscopists with expertise in EET, pathologists with expertise in BE neoplasia, with access to multidisciplinary care.
  • Histologic diagnosis of BE dysplasia or early cancer should be confirmed by an expert pathologist.
  • In patients undergoing management of dysplastic BE, optimize reflux control with medication, lifestyle modifications, and assessing adherence.
  • Before embarking on EET, discuss risks and benefits of EET, need for adherence with reflux management, expected outcomes, need for continued surveillance after completion of EET, with adequate time to assess patient values and preferences.
  • The goal of EET should be complete eradication of intestinal metaplasia and neoplasia.
  • Failure to achieve complete eradication of intestinal metaplasia should prompt reassessment and optimization of reflux control.
  • Endoscopists and practices performing EET are encouraged to monitor key outcomes and quality metrics, including complete eradication of intestinal metaplasia and neoplasia and adverse events.

Overview

Title

Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia

Authoring Organization